Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (51-60 of 315) with videos related to

Pageof 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trialsPaul A Clarke, Paul Workman
Nature|October 21, 2011
Chemical biology: Many faces of a cancer-supporting proteinJohn F Darby, Paul Workman
Trends in Pharmacological Sciences|March 27, 2021
A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2Marco P Licciardello, Paul Workman
Current Cancer Drug Targets|October 8, 2003
The clinical applications of heat shock protein inhibitors in cancer - present and futureUdai Banerji, Ian Judson, Paul Workman
Nature Chemical Biology|August 30, 2011
Epigenetics: Targeting leukemia on the DOTJon Travers, Julian Blagg, Paul Workman
Cancer Cell|February 28, 2025
Probing cancer with small-molecule tools-Progress and challengesSusanne Müller, Domenico Sanfelice, Paul Workman
Drug Discovery Today|January 17, 2012
HSP90 inhibition: two-pronged exploitation of cancer dependenciesJon Travers, Swee Sharp, Paul Workman
Current Topics in Medicinal Chemistry|July 18, 2006
Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancerEdward McDonald, Paul Workman, Keith Jones
Biomarkers in Medicine|May 19, 2010
Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug developmentDebashis Sarker, Simon Pacey, Paul Workman
Current Cancer Drug Targets|October 8, 2003
Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspectiveAlison Maloney, Paul A Clarke, Paul Workman
Pageof 32

Showing results (51-60 of 315) with videos related to

Sort By:
Pageof 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trialsPaul A Clarke, Paul Workman
Nature|October 21, 2011
Chemical biology: Many faces of a cancer-supporting proteinJohn F Darby, Paul Workman
Trends in Pharmacological Sciences|March 27, 2021
A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2Marco P Licciardello, Paul Workman
Current Cancer Drug Targets|October 8, 2003
The clinical applications of heat shock protein inhibitors in cancer - present and futureUdai Banerji, Ian Judson, Paul Workman
Nature Chemical Biology|August 30, 2011
Epigenetics: Targeting leukemia on the DOTJon Travers, Julian Blagg, Paul Workman
Cancer Cell|February 28, 2025
Probing cancer with small-molecule tools-Progress and challengesSusanne Müller, Domenico Sanfelice, Paul Workman
Drug Discovery Today|January 17, 2012
HSP90 inhibition: two-pronged exploitation of cancer dependenciesJon Travers, Swee Sharp, Paul Workman
Current Topics in Medicinal Chemistry|July 18, 2006
Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancerEdward McDonald, Paul Workman, Keith Jones
Biomarkers in Medicine|May 19, 2010
Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug developmentDebashis Sarker, Simon Pacey, Paul Workman
Current Cancer Drug Targets|October 8, 2003
Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspectiveAlison Maloney, Paul A Clarke, Paul Workman
Pageof 32